Ribosome Research Centre Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
- Paid Up Capital ₹ 2.40 Cr
- Company Age 14 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 20.96 Cr
- Satisfied Charges ₹ 1.00 M
- Revenue Growth -15.41%
- Profit Growth 42.82%
- Ebitda 233.73%
- Net Worth -214.70%
- Total Assets -7.27%
About Ribosome Research Centre
Ribosome Research Centre Private Limited (RRCPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 January 2011 and has a history of 14 years and one month. Its registered office is in Surat, Gujarat, India.
The Corporate was formerly known as Ribosome Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.40 Cr.
The company currently has active open charges totaling ₹20.96 Cr. The company has closed loans amounting to ₹1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Rameshbhai Balar, Ghanshyambhai Navadiya, Nagjibhai Jivani, and Four other members serve as directors at the Company.
Company Details
- Location
Surat, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230GJ2011PTC063569
- Company No.
063569
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jan 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
What products or services does Ribosome Research Centre Private Limited offer?
Ribosome Research Centre Private Limited offers a wide range of products and services, including Sensors & Transducers, Proximity Switches.
Who are the key members and board of directors at Ribosome Research Centre?
Board Members (7)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Rameshbhai Balar ![]() | Director | 01-Oct-2022 | Current |
Ghanshyambhai Navadiya ![]() | Director | 10-Jan-2011 | Current |
Nagjibhai Jivani ![]() | Director | 10-Jan-2011 | Current |
Dinesh Sutaria ![]() | Director | 10-Jan-2011 | Current |
Chandubhai Saliya ![]() | Director | 01-Oct-2022 | Current |
Kishor Mavani ![]() | Director | 14-Oct-2019 | Current |
Financial Performance of Ribosome Research Centre.
Ribosome Research Centre Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 15.41% decrease. The company also saw a substantial improvement in profitability, with a 42.82% increase in profit. The company's net worth observed a substantial decline by a decrease of 214.7%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Ribosome Research Centre?
In 2022, Ribosome Research Centre had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹20.96 Cr
₹0.10 Cr
Charges Breakdown by Lending Institutions
- Others : 20.96 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
25 Oct 2019 | Others | ₹2.10 Cr | Open |
19 Jan 2019 | Others | ₹3.70 Cr | Open |
22 Feb 2018 | Others | ₹5.29 Cr | Open |
06 Feb 2018 | Others | ₹9.87 Cr | Open |
23 Dec 2011 | The Surat District Co-Operative Bank Ltd. | ₹1.00 M | Satisfied |
How Many Employees Work at Ribosome Research Centre?
Ribosome Research Centre has a workforce of 4 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Ribosome Research Centre, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ribosome Research Centre's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.